Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 83.21 as of 2026-10-06T19:16:14.558Z.
Consensus retrieved: 2026-10-06T10:18:13.000Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:16:14.558Z.
Quote observation: 2026-10-06T19:15:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: aa9bc7f9cefff507f8a4fe626b62717351a0ace1a98d881cea9fd3b4864bb5d1
Forward PE Ratio (83.21) = Dated Quote Price ($4.66) / Consensus Forward EPS ($0.06)
FORWARD PE RATIO
83.21
SECTOR MEDIAN · HEALTHCARE
19.84
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+319.41%
vs the sector median at left
Clover Health Investments, Corp.
Market Cap
$2.42B
Forward PE Ratio
83.21
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Clover Health Investments, Corp. (CLOV) | $2.42B | 83.21 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.39B | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 12.76 |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.46B | 16.56 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | N/A |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 30.94 |
| Liquidia Corporation (LQDA)vs › | $2.31B | 10.46 |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.51B | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 10.02 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
83.2
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.66, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.06 | $0.05 – $0.06 | 2 | 83.2x |
| 2027-12-31 | $0.10 | $0.10 – $0.10 | 2 | 46.5x |
| 2028-12-31 | $0.17 | $0.09 – $0.26 | 3 | 28.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
